In NSCLC patients lacking a particular gene mutation or exhibiting resistance to EGFR/ALK/ROS1-TKIs, the therapeutic efficacy of CRT combined with anlotinib may surpass that of CRT monotherapy. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.